-
51.发明申请公开(公告)号：US20190262406A1
公开(公告)日：2019-08-29
申请号：US16138962
申请日：2018-09-21
申请人： CELULARITY, INC.
发明人： James W. Edinger , Robert J. Hariri , Jia-Lun Wang , Qian Ye , Kristen S. Labazzo , Marian Pereira , Sascha Dawn Abramson
IPC分类号： A61K35/50 , A61K47/36 , A61K47/42 , C12N5/0775 , A61L27/38 , C12N5/073 , C12N5/077 , A61K9/00
摘要： Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.
-
公开(公告)号：US20180273903A1
公开(公告)日：2018-09-27
申请号：US15857516
申请日：2017-12-28
申请人： Celularity, Inc.
发明人： Xiaokui Zhang , Qian Ye , Tianjian Li , Chuan Wang , Mini Bharathan , Uri Herzberg
IPC分类号： C12N5/0783 , A61K35/17 , A61P35/00 , A61K45/06 , C07K14/735
CPC分类号： C12N5/0646 , A61K35/17 , A61K45/06 , A61P35/00 , C07K14/70535 , C12N15/113 , C12N15/1138 , C12N2310/20 , C12N2501/70 , C12N2510/00 , C12N2740/16043
摘要： Provided herein are genetically modified (GM) natural killer (NK) cells and methods of producing populations of GM NK cells. Further provided herein are methods of using the GM NK cells described herein, to, e.g., suppress the proliferation of tumor cells, or to inhibit pathogen infection, e.g., viral infection. In certain alternatives, GM NK cells provided herein lack expression of CBLB, NKG2A and/or TGFBR2 and/or function or show reduced expression and/or function of CBLB, NKG2A and/or TGFBR2. In certain alternatives, GM NK cells provided herein comprise modified CD16.
-
公开(公告)号：US20230355759A1
公开(公告)日：2023-11-09
申请号：US17597968
申请日：2020-07-31
申请人： CELULARITY INC.
发明人： Xuan GUO , Srinivas SOMANCHI , Rohit MATHUR , Shuyang HE , Qian YE , Xiaokui ZHANG , Salvatore ROTONDO , Hemlata RANA , Weifang LING , James W. EDINGER , Robert J. HARIRI , Andrea DIFIGLIA
IPC分类号： A61K39/00 , C12N5/0783 , C12N15/86 , A61P35/00 , A61K45/06
CPC分类号： A61K39/4613 , C12N5/0646 , C12N15/86 , A61P35/00 , A61K39/4637 , A61K39/4644 , A61K45/06 , C12N2510/00 , C12N2740/15043 , A61K2239/26
摘要： Provided herein are populations of placental-derived natural killer cells comprising a cleavage resistant CD16. Also provided are methods of treating diseases, disorders or conditions in a human subject comprising administering to the subject an effective amount of a population of placental-derived natural killer cells comprising a cleavage resistant CD16 to the subject so as thereby to provide an effective treatment of the to the subject. The cells, such as CYNK cells, can be placental CD34+ cell-derived natural killer (NK) cells. The diseases, disorders or conditions include cancers such as multiple myeloma and lymphoma. The present invention also provides compositions comprising populations of placental-derived natural killer cells comprising a cleavage resistant CD16 for the treatment of a subject and methods of their use.
-
公开(公告)号：US11723930B2
公开(公告)日：2023-08-15
申请号：US16752326
申请日：2020-01-24
申请人： CELULARITY, INC.
发明人： James W. Edinger , Robert J. Hariri , Jia-Lun Wang , Qian Ye , Herbert Faleck
CPC分类号： A61K35/50 , A61K35/644 , A61K38/21 , A61K45/06 , C12N5/0605 , A61K2035/122 , C12N2500/25 , C12N2500/36 , C12N2501/11 , C12N2501/135 , C12N2501/39 , A61K35/644 , A61K2300/00 , A61K35/50 , A61K2300/00 , A61K38/21 , A61K2300/00
摘要： Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.
-
公开(公告)号：US20230090316A1
公开(公告)日：2023-03-23
申请号：US18057487
申请日：2022-11-21
申请人： Celularity Inc.
IPC分类号： A61K35/51 , A61K35/50 , A61K38/18 , A61K35/18 , A61K33/26 , A61K31/714 , A61P11/00 , A61K45/06
摘要： The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood stem cells, particularly autologous cord blood cells, and placental stem cells for the treatment of premature infants.
-
公开(公告)号：US20220273716A1
公开(公告)日：2022-09-01
申请号：US17630079
申请日：2020-07-27
申请人： Celularity Inc.
发明人： Srinivas SOMANCHI , Xuan GUO , Shuyang HE , Rohit MATHUR , Xiaokui ZHANG , Hemlata RANA , Weifang LING , James W. EDINGER , Robert J. HARIRI , Andrea DIFIGLIA
IPC分类号： A61K35/17 , C12N5/0783 , C12N15/62 , C12N15/86
摘要： Provided herein are methods of treating cancer in a human subject comprising administering to the subject an effective amount of human placental-derived natural killer cells comprising a CD38 chimeric antigen receptor (CAR) to the subject so as thereby to provide an effective treatment of the cancer in the subject. The cells, such as CYNK cells, can be placental CD34+ cell-derived natural killer (NK) cells. The cancers to be treated include multiple myeloma and lymphoma. The present invention also provides compositions comprising human placental-derived natural killer cells comprising a CD38 chimeric antigen receptor (CAR) or the treatment of multiple myeloma and lymphoma and methods of their use.
-
公开(公告)号：US20220265712A1
公开(公告)日：2022-08-25
申请号：US17619242
申请日：2020-06-15
申请人： CELULARITY INC.
发明人： Robert J. Hariri , Xiaokui Zhang , Nassir HABBOUBI , Catherine Balint , Erica Rave , Christopher Keller , Solveig Ericson , Sharmila Koppisetti , Stacy Herb , William van der Touw , Shuyang He , Junhong Zhu
IPC分类号： A61K35/17 , C12N5/0783 , A61P35/02
摘要： Provided herein are methods of treating cancer in a human subject comprising administering to the subject an effective amount of CYNK cells to the subject so as thereby to provide an effective treatment of the cancer in the subject. The CYNK cells can be placental-derived natural killer (NK) cells or placental CD34+ cell-derived natural killer (NK) cells. The cancers to be treated include multiple myeloma and acute myeloid leukemia. The present invention also provides compositions comprising CYNK cells for the treatment of multiple myeloma and acute myeloid leukemia and methods of their use.
-
公开(公告)号：US20220251104A1
公开(公告)日：2022-08-11
申请号：US17297841
申请日：2019-11-29
申请人： Celularity Inc.
发明人： Robert J. HARIRI , Xiaokui ZHANG , James EDINGER
IPC分类号： C07D495/04 , C07D491/048 , C07D491/04 , C07D487/04 , C07D473/30 , C07D409/04 , C07D401/12 , C07D401/14
摘要： Disclosed herein are new aromatic compounds, compositions that include one or more aromatic compounds, and methods of synthesizing the same. Also disclosed herein are methods of increasing and/or expanding cells, including stem cells, hematopoietic stem cells, progenitor cells, and placenta or cord blood-derived cells, with one or more compounds or compositions described herein. Also disclosed herein are methods of increasing and/or expanding differentiated hematopoietic cells with one or more compounds or compositions described herein.
-
公开(公告)号：US20220096564A1
公开(公告)日：2022-03-31
申请号：US17302855
申请日：2021-05-13
申请人： Celularity Inc.
发明人： James W. EDINGER , Robert J. HARIRI , Jia-Lun WANG , Qian YE , Kristen S. LABAZZO , Marian PEREIRA , Sasha Dawn ABRAMSON
IPC分类号： A61K35/50 , C12N5/0775 , A61L27/38 , C12N5/073 , C12N5/077 , A61K9/00 , A61K47/36 , A61K47/42
摘要： Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.
-
公开(公告)号：US20220072063A1
公开(公告)日：2022-03-10
申请号：US17455322
申请日：2021-11-17
申请人： Celularity Inc.
摘要： Provided herein are methods of using CD10+, CD34−, CD105+, CD200+ tissue culture plastic-adherent placental cells, e.g. placental stem cells, in the treatment of diabetic peripheral neuropathy (DPN).
-
-
-
-
-
-
-
-
-
搜索结果
77 条记录 (耗时 0.016 秒)
